OAC discontinuation post-AF ablation may be considered in low-risk, first-time ablation patients arrhythmia-free at 12 months, but lacks validated monitoring strategies.
Is it safe to discontinue oral anticoagulation in patients with atrial fibrillation who remain arrhythmia-free after ablation?
Before considering OAC discontinuation after AF ablation, patients should meet strict criteria including 12-month arrhythmia-free status, low thromboembolic risk, and access to intensified rhythm monitoring.
Absolute Event Rate: 0% vs 0%
Hospital pharmacists increasingly receive questions about oral anticoagulation (OAC) discontinuation in patients with atrial fibrillation (AF) who remain arrhythmia-free after ablation. Two recent trials, ALONE-AF and OCEAN, reported low annual stroke rates in selected post-ablation cohorts, suggesting limited added stroke protection from OAC in this group. Both studies have key limitations: selective low-risk patient populations, insufficient power for thromboembolic events, limited external validity to older AF patients, and methodological concerns including ALONE-AF's fragility index and OCEAN's comparator choice. Before OAC discontinuation is considered, multiple criteria should be met: first-time ablation with documented 12 month arrhythmia-free status, low thromboembolic risk, absence of prior cerebrovascular events and access to intensified rhythm monitoring, acknowledging that no validated monitoring strategy currently exists to guide anticoagulation decisions after ablation.
Linden et al. (Fri,) reported a other. OAC discontinuation post-AF ablation may be considered in low-risk, first-time ablation patients arrhythmia-free at 12 months, but lacks validated monitoring strategies.